Chair: Jan-Henning Klusmann

Prof. Dr. Thomas Mercher
Ontogeny-dependent susceptibility to fusion oncogenes controls pediatric myeloid leukemia

Institut Gustave Roussy; Villejuif

Chair: Thomas Sternsdorf

2.a Mutational and transcriptomic landscapes in hematopoietic cells of Fanconi anemia patients.
Mittapalli, VR; Freiburg

2.b Mapping the single cell transcriptome reveals the cellular composition of ATRT subgroups
Buellesbach, A; Heidelberg

2.c Giant cell glioblastoma does not represent a distinct entity but stratifies into different genetically defined entities
Wiedey, A; Bonn

2.d WNT Medulloblastoma: More than just β-Catenin Mutations – Rare Genetic Features in the Focus
Goschzik, T; Bonn

2.e Epigenetics profiling for minimal residual disease in paediatric acute myeloid leukaemia
Al Ameri, M; London

Chair: Owen Williams

3.a Splicing factors of the SF3b complex PHF5A and SF3B1 regulate the DNA damage response in ALL
Moorthy, S; Newcastle upon Tyne

3.b Inactivation of Nsd1 impairs terminal erythroid maturation and induces erythroleukemia
Tauchmann, S; Basel

3.c TRIM28 haploinsufficiency predisposes to Wilms tumor
Metzler, M; Erlangen

3.d CRISPR-mediated genome editing of t(4;11) in human prenatal and perinatal hematopoietic stem/progenitor cells
Torres-Ruiz, R; Barcelona

3.e Therapeutic application of the tumour suppressive miR-193b in acute myeloid leukaemia
Issa, H; Halle

3.f Genome-wide CRISPR screen in patient derived cells reveals the mechanism of ALL chemoresistance
Szoltysek, K; Newcastle upon Tyne

3.g GCRISPRi screen to identify functional long noncoding RNAs in pediatric acute myeloid leukemia
Ng, M; Halle

Chair: Torsten Pietsch

4.a Tumour Necrosis Factor receptor (TNFR)-signalling dependent killing in T- cell acute lymphoblastic leukaemia (T-ALL)
Krippner-Heidenreich, A; Utrecht

4.b iPSC Model of Stepwise Leukemia Development in Congenital Neutropenia Reveals BAALC as a Key Mediator of Leukemogenesis
Dannenmann, B; Tübingen

4.c Targeting c-MYB in Acute Leukaemia through Drug Repositioning
Clesham KJ; London

4.d Functional analysis of class I HDAC inhibition in group 3 medulloblastoma to identify synergistic drug combinations
Vollmer, J; Heidelberg

4.e Screening assay to identify potential Taspase1 inhibitors
Luciano, V; Frankfurt

4.f Analyzing the therapeutic efficacy of navitoclax and MCL-1 inhibitors in juvenile myelomonyctic leukemia
Wu, Y; Freiburg

4.g Establishment of new therapeutic options for the treatment of Myeloid Leukemia in Down syndrome (ML-DS)
Samulowski, D; Halle

Chair: Roland Kappler

5.a Masked hypodiploidy against uniparental disomies in hyperdiploid ALL: Observations from the diagnostics perspective
Schieck, M; Hannover

5.b Large amplicon droplet digital PCR for DNA-based monitoring of pediatric chronic myeloid leukemia (CML)
Krumbholz, M; Erlangen

5.c Stratification and prognosis of IGH-DUX4 positive acute lymphoblastic leukemia in children
Müller, J; Kiel

5.d Multiplex droplet digital PCR-based targeted enrichment NGS for identification of tumor markers in Ewing sarcoma (EwS)
Eiblwieser, J; Erlangen

5.e Machine learning algorithms for the automated classification of pediatric anemia
Zierk, J; Erlangen

5.f Identification of the genetic mechanisms linked to the occurrence of H3.3K27M mutation in pediatric diffuse intrinsic pontine gliomas
Kubiak, K; Göttingen

Chair: Deepali Pal

6.a Deciphering the interactive network of the DLK1-DIO3 locus in hematopoiesis and pediatric acute megakaryoblastic leukemia
Verboon LJ; Halle

6.b Identification of GATA1s interaction partners in Down syndrome-associated myeloid leukemia
Bräuer-Hartmann, D; Halle

6.c Isolation and characterization of tumor-derived exosomes from a patient-derived xenograft mouse model of acute leukemia
Bartholomé, R; München

6.d Interrogating the role of chromatin regulator BRD4 in the DNA damage response in medulloblastoma
Vu-Han, T-L; Hamburg

6.e Analyzing the effects of oncogenic SHP2 on apoptosis signaling during malignant transformation
Koleci, N; Freiburg

6.f Cooperativity between miR-125b and Gata1s in the pathogenesis of Down syndrome-associated myeloid leukemia
Alejo-Valle, O; Halle

Chair: Karl Welte

Senior-Prof. em. Dr. Meinolf Suttorp
Do you know a chimera?

Pediatric Hematology and Oncology, Medical Faculty, Technical University Dresden; Dresden

Chair:  Olaf Heidenreich

8.a Development of a novel central nervous system (CNS)-targeted CD19-antibody (AB) in acute lymphoblastic leukemia (ALL)
Winterberg, D; Kiel

8.b CD19 and CD22-directed bispecific CAR for B-cell acute lymphoblastic leukemia
Zanetti, SR; Barcelona

8.c Low regulatory T-cells are associated with improved survival of neuroblastoma patients treated with anti-GD2 antibodies
Troschke-Meurer. S; Greifswald

8.d CRISPR/Cas9 Gene-modification Platform of ELANE Mutations in iPSCs and HSPCs of Severe Congenital Neutropenia Patients
Nasri, M; Tübingen

8.e Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies
Heymann, J; Kiel

8.f Blockade of suppressive myeloid cells is effective against neuroblastoma
von Lojewski, L; Tübingen

Chair: Jasper de Boer

9.a Too little is too much: Leukemogenesis in the Gata2 syndrome
Weiss, JM; Freiburg

9.b Using acute promyelocytic leukemia to study the H3.3 histone chaperone system and its role in pediatric malignancies
Cui, W; Hamburg

9.c Functional characterization of RUNX1 variants in the context of FPDMM
Decker, M; Hannover

9.d FOS and FOSB are linked with CNS-infiltration and inferior prognosis in childhood T-cell acute lymphoblastic leukemia
Spory, L; Kiel

9.e Deciphering role of lncRNAs in pediatric AML
Bhayadia, R; Halle

9.f Genomic characterisation of lineage switched MLL-rearranged leukemias
Tirtakusuma, R; Newcastle upon Tyne

9.g Downstream effect of CSF3R and RUNX1 mutations that underlie leukemic transformations in congenital neutropenia (CN)
Ritter, MU; Tübingen

Chair: Markus Metzler

10.a Identification of a new splice variant of the human transcription factor ONECUT2
Lein, P; Halle

10.b NAMPT-mediated LMO2 deacetylation is indispensable for hematopoiesis and T-ALL leukemogenesis
Morishima, T; Tübingen

10.c GADD45b plays an essential role in the G-CSF triggered granulocytic differentiation of human hematopoietic cells
Mir, P; Tübingen

10.d Tripartite motif-containing 71 (TRIM71) is a major factor of oncogenic activity in human hepatoblastoma
Jiang, T; München

10.e Chromosome structure and mitotic defects are major pathogenic mechanisms in hyperdiploid childhood B-ALL.
Molina, O; Barcelona

Chair: Julia Skokowa

11.a Investigating HDACi and dnTaspase1 for the treatment of (4;11) leukemic cells
Wilhelm, A; Frankfurt

11.b Dasatinib and dexamethasone offer a novel therapeutic strategy for T-cell acute lymphoblastic leukaemia
Yuzhe, S; Newcastle upon Tyne

11.c Drug repositioning in infant leukaemia
Looi-Somoye, R; London

11.d Synthetic lethality of Wnt pathway activation and asparaginase in drug-resistant acute leukemias
Hinze, L; Hannover

11.e A human BM-iPSC-derived oncogenic niche identifies CDH2 as a therapeutic niche target in leukemia
Pal, D; Newcastle upon Tyne

11.f Inhibition of the polycomb repressive complex 1 (PRC1) as a therapeutic option in childhood liver tumors
Bentrop, M; München